The Complete Metformin Guide
Update: 2019-10-02
Description
Episode 282 brings you the COMPLETE guide on metformin! Every possible interaction, MoA, and question has been answered and summarized here on this episode! My goal for this is to truly summarize the full picture of metformin as too many people demonize it for reasons that literally are so insignificant, they should barely even be paid a notice. So with that in mind, get your notepads ready, this one is FULL of information! And yes, a few references for those of you that wish to read further!
REFERENCES
1.
Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2011;13(3):221–228. [PubMed]
2. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One. 2013;8(8):e71583. [PMC free article] [PubMed]
3. Cohen RD, Woods HF. Clinical and biochemical aspects of lactic acidosis. Philadelphia: Blackwell Scientific Publications; 1976.
4. Metformin hydrochoride. Boxed warning. [October 6, 2015]. Available at: https://dailymed<wbr />.nlm<wbr />.nih.gov/dailymed/fda/fdaDrugXsl<wbr />.cfm?setid<wbr />=b8004451-7b26-425b-b5ea-cbb1b08e30e3&type=display.
5. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312(24):2668–2675. [PMC free article] [PubMed]
6. Gan SC, Barr J, Arieff AI, Pearl RG. Biguanide-associated lactic acidosis. Case report and review of the literature. Arch Intern Med. 1992;152(11):2333–2336. [PubMed]
7. Goergen SK, Rumbold G, Compton G, Harris C. Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin. Radiology. 2010;254(1):261–269. [PubMed]
8. Kajbaf F, Arnouts P, de Broe M, Lalau JD. Metformin therapy and kidney disease: a review of guidelines and proposals for metformin withdrawal around the world. Pharmacoepidemiol Drug Saf. 2013;22(10):1027–1035.[PubMed]
9. Calabrese AT, Coley KC, DaPos SV, Swanson D, Rao RH. Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med. 2002;162(4):434–437. [PubMed]
10. Emslie-Smith AM, Boyle DI, Evans JM, Sullivan F, Morris AD. Contraindications to metformin therapy in patients with Type 2 diabetes--a population-based study of adherence to prescribing guidelines. Diabet Med. 2001;18(6):483–488. [PubMed]
11. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. [June 16, 2016]. Available at: http://www<wbr />.fda.gov/Drugs<wbr />/DrugSafety/ucm493244.htm.
12. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med. 2006;354(23):2473–2483. [PubMed]
13. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabtologia. 2015;58(3):429–442. [PubMed]
14. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis. 2012;60(5):850–886. [PubMed]
15. Flory JH, Hennessy S. Metformin use reduction in mild to moderate renal impairment: possible inappropriate curbing of use based on food and drug administration contraindications. JAMA Intern Med. 2015;175(3):458–459. [PubMed]
16. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;(4) CD002967. [PubMed]
17. Organization for Economic Cooperation and Development. [October 20, 2015]. Available at: http://www<wbr />.oecd.org/about<wbr />/membersandpartners<wbr />/list-oecd-member-countries.htm.
18. Eurich DT, Weir DL, Majumdar SR, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. 2013;6(3):395–402. [PubMed]
19. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–470. [PubMed]
20. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612. [PMC free article] [PubMed]
21. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. [PMC free article] [PubMed]
22. Agency for Healthcare Research and Quality. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality; [October 6, 2015]. Available at: http://www<wbr />.effectivehealthcare<wbr />.ahrq.gov/index<wbr />.cfm/search-for-guides-reviews-and-reports<wbr />/?pageaction=displayproduct&productid=318.
23. Santaguida PL, Raina P, Ismaila P. The Development of the McHarm Quality Assessment Scale for adverse events. 2012
24. Viswanathan M, Ansari M, Berkman N. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville (MD): Agency for Healthcare Research and Qu
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
